APO RESEARCH · REPORT
CRISPR and CRISPR-Associated (Cas) Genes
This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.
Product & engineering
Understand the product.
This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.
Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid.
The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.
Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.
By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.
Selected research
Industry Research
CRISPR and CRISPR-Associated (Cas) Genes Industry Research Report 2026
Market perspective
This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.
Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid.
The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.
Read the full market overview
Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.
By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.
Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics and Intellia therapeutics, Inc. are the top 5 players of CRISPR and CRISPR-Associated (Cas) Genes, with about 63% market shares.
CRISPR And CRISPR-Associated (Cas) Genes industry is relatively concentrated, manufacturers are mostly in the Europe and North America. Among them, North America region accounted for more than 45% of the total market of global CRISPR And CRISPR-Associated (Cas) Genes.
Report Scope
This report quantifies the global CRISPR and CRISPR-Associated (Cas) Genes market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to CRISPR and CRISPR-Associated (Cas) Genes.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
CRISPR and CRISPR-Associated (Cas) Genes Market by Company
Thermo Fisher Scientific
Editas Medicine
Caribou Biosciences
CRISPR therapeutics
Intellia therapeutics, Inc.
Cellectis
Horizon Discovery Plc
Sigma Aldrich
Precision Biosciences
Genscript
Sangamo Biosciences Inc.
Lonza Group Limited
Integrated DNA Technologies
New England Biolabs
Origene Technologies
CRISPR and CRISPR-Associated (Cas) Genes Segment by Type
Genome Editing
Genetic engineering
gRNA Database/Gene Librar
CRISPR Plasmid
Human Stem Cells
Genetically Modified Organisms/Crops
Cell Line Engineering
CRISPR and CRISPR-Associated (Cas) Genes Segment by Application
Biotechnology Companies
Pharmaceutical Companies
Academic Institutes
Research and Development Institutes
CRISPR and CRISPR-Associated (Cas) Genes Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CRISPR and CRISPR-Associated (Cas) Genes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CRISPR and CRISPR-Associated (Cas) Genes and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CRISPR and CRISPR-Associated (Cas) Genes.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Genome Editing
- Genetic engineering
- gRNA Database/Gene Librar
- CRISPR Plasmid
- Human Stem Cells
- Genetically Modified Organisms/Crops
- Cell Line Engineering
Applications
- Biotechnology Companies
- Pharmaceutical Companies
- Academic Institutes
- Research and Development Institutes
Companies covered
- Thermo Fisher Scientific
- Editas Medicine
- Caribou Biosciences
- CRISPR therapeutics
- Intellia therapeutics, Inc.
- Cellectis
- Horizon Discovery Plc
- Sigma Aldrich
- Precision Biosciences
- Genscript
- Sangamo Biosciences Inc.
- Lonza Group Limited
- Integrated DNA Technologies
- New England Biolabs
- Origene Technologies
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 CRISPR and CRISPR-Associated (Cas) Genes by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Genome Editing
- 2.2.3 Genetic engineering
- 2.2.4 gRNA Database/Gene Librar
- 2.2.5 CRISPR Plasmid
- 2.2.6 Human Stem Cells
- 2.2.7 Genetically Modified Organisms/Crops
- 2.2.8 Cell Line Engineering
- 2.3 CRISPR and CRISPR-Associated (Cas) Genes by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Biotechnology Companies
- 2.3.3 Pharmaceutical Companies
- 2.3.4 Academic Institutes
- 2.3.5 Research and Development Institutes
- 2.4 Assumptions and Limitations
3 CRISPR and CRISPR-Associated (Cas) Genes Breakdown Data by Type
- 3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Historic Market Size by Type (2021-2026)
- 3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Forecasted Market Size by Type (2027-2032)
4 CRISPR and CRISPR-Associated (Cas) Genes Breakdown Data by Application
- 4.1 Global CRISPR and CRISPR-Associated (Cas) Genes Historic Market Size by Application (2021-2026)
- 4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Perspective (2021-2032)
- 5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Growth Trends by Region
- 5.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 CRISPR and CRISPR-Associated (Cas) Genes Historic Market Size by Region (2021-2026)
- 5.2.3 CRISPR and CRISPR-Associated (Cas) Genes Forecasted Market Size by Region (2027-2032)
- 5.3 CRISPR and CRISPR-Associated (Cas) Genes Market Dynamics
- 5.3.1 CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
- 5.3.2 CRISPR and CRISPR-Associated (Cas) Genes Market Drivers
- 5.3.3 CRISPR and CRISPR-Associated (Cas) Genes Market Challenges
- 5.3.4 CRISPR and CRISPR-Associated (Cas) Genes Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top CRISPR and CRISPR-Associated (Cas) Genes Players by Revenue
- 6.1.1 Global Top CRISPR and CRISPR-Associated (Cas) Genes Players by Revenue (2021-2026)
- 6.1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Players (2021-2026)
- 6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of CRISPR and CRISPR-Associated (Cas) Genes Head Office and Area Served
- 6.4 Global CRISPR and CRISPR-Associated (Cas) Genes Players, Product Type & Application
- 6.5 Global CRISPR and CRISPR-Associated (Cas) Genes Manufacturers Established Date
- 6.6 Global CRISPR and CRISPR-Associated (Cas) Genes Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America CRISPR and CRISPR-Associated (Cas) Genes Market Size (2021-2032)
- 7.2 North America CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2021-2026)
- 7.4 North America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Market Size (2021-2032)
- 8.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2021-2026)
- 8.4 Europe CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Size (2021-2032)
- 9.2 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2021-2026)
- 9.4 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America CRISPR and CRISPR-Associated (Cas) Genes Market Size (2021-2032)
- 10.2 South America CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2021-2026)
- 10.4 South America CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Market Size (2021-2032)
- 11.2 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2021-2026)
- 11.4 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Thermo Fisher Scientific
- 12.1.1 Thermo Fisher Scientific Company Information
- 12.1.2 Thermo Fisher Scientific Business Overview
- 12.1.3 Thermo Fisher Scientific Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.1.4 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.1.5 Thermo Fisher Scientific Recent Developments
- 12.2 Editas Medicine
- 12.2.1 Editas Medicine Company Information
- 12.2.2 Editas Medicine Business Overview
- 12.2.3 Editas Medicine Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.2.4 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.2.5 Editas Medicine Recent Developments
- 12.3 Caribou Biosciences
- 12.3.1 Caribou Biosciences Company Information
- 12.3.2 Caribou Biosciences Business Overview
- 12.3.3 Caribou Biosciences Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.3.4 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.3.5 Caribou Biosciences Recent Developments
- 12.4 CRISPR therapeutics
- 12.4.1 CRISPR therapeutics Company Information
- 12.4.2 CRISPR therapeutics Business Overview
- 12.4.3 CRISPR therapeutics Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.4.4 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.4.5 CRISPR therapeutics Recent Developments
- 12.5 Intellia therapeutics, Inc.
- 12.5.1 Intellia therapeutics, Inc. Company Information
- 12.5.2 Intellia therapeutics, Inc. Business Overview
- 12.5.3 Intellia therapeutics, Inc. Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.5.4 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.5.5 Intellia therapeutics, Inc. Recent Developments
- 12.6 Cellectis
- 12.6.1 Cellectis Company Information
- 12.6.2 Cellectis Business Overview
- 12.6.3 Cellectis Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.6.4 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.6.5 Cellectis Recent Developments
- 12.7 Horizon Discovery Plc
- 12.7.1 Horizon Discovery Plc Company Information
- 12.7.2 Horizon Discovery Plc Business Overview
- 12.7.3 Horizon Discovery Plc Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.7.4 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.7.5 Horizon Discovery Plc Recent Developments
- 12.8 Sigma Aldrich
- 12.8.1 Sigma Aldrich Company Information
- 12.8.2 Sigma Aldrich Business Overview
- 12.8.3 Sigma Aldrich Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.8.4 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.8.5 Sigma Aldrich Recent Developments
- 12.9 Precision Biosciences
- 12.9.1 Precision Biosciences Company Information
- 12.9.2 Precision Biosciences Business Overview
- 12.9.3 Precision Biosciences Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.9.4 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.9.5 Precision Biosciences Recent Developments
- 12.10 Genscript
- 12.10.1 Genscript Company Information
- 12.10.2 Genscript Business Overview
- 12.10.3 Genscript Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.10.4 Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.10.5 Genscript Recent Developments
- 12.11 Sangamo Biosciences Inc.
- 12.11.1 Sangamo Biosciences Inc. Company Information
- 12.11.2 Sangamo Biosciences Inc. Business Overview
- 12.11.3 Sangamo Biosciences Inc. Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.11.4 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.11.5 Sangamo Biosciences Inc. Recent Developments
- 12.12 Lonza Group Limited
- 12.12.1 Lonza Group Limited Company Information
- 12.12.2 Lonza Group Limited Business Overview
- 12.12.3 Lonza Group Limited Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.12.4 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.12.5 Lonza Group Limited Recent Developments
- 12.13 Integrated DNA Technologies
- 12.13.1 Integrated DNA Technologies Company Information
- 12.13.2 Integrated DNA Technologies Business Overview
- 12.13.3 Integrated DNA Technologies Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.13.4 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.13.5 Integrated DNA Technologies Recent Developments
- 12.14 New England Biolabs
- 12.14.1 New England Biolabs Company Information
- 12.14.2 New England Biolabs Business Overview
- 12.14.3 New England Biolabs Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.14.4 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.14.5 New England Biolabs Recent Developments
- 12.15 Origene Technologies
- 12.15.1 Origene Technologies Company Information
- 12.15.2 Origene Technologies Business Overview
- 12.15.3 Origene Technologies Revenue in CRISPR and CRISPR-Associated (Cas) Genes Business (2021-2026)
- 12.15.4 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
- 12.15.5 Origene Technologies Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst